Overall, these data suggest the sensitivity of EML4-ALK-driven cell lines to combining LOR and AKT VIII inhibitors and the importance of AKT/PI3K signalling pathway in EML4-ALK+positive NSCLC, specifically in the EML4-ALK V3 cell line (H2228). The gene discussed is ALK; the disease is non-small cell lung carcinoma.